An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).

drug protocol number
CINC424A2401
drug sponsor
Novartis
drug study
Ruxolitinib
drug trial site
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
drug status
Ongoing
drug phase